Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy

D. J. Storey*, D. B. McLaren, M A Atkinson, I. Butcher, L. C. Frew, J. F. Smyth, M. Sharpe

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The purpose of the study was to determine the prevalence and associations of clinically relevant fatigue (CRF) in men with biochemically controlled prostate cancer on long-term androgen deprivation therapy (ADT).

Patients and methods: One hundred and ninety-eight men were surveyed and the prevalence of CRF (Brief Fatigue Inventory score >3) determined. Associations with other measures (Hospital Anxiety and Depression Scale; International Prostate Symptom Score; European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; Brief Pain Inventory worst pain; clinical and demographic information) were explored in univariate and multivariate analyses.

Results: Eight-one per cent (160 of 198) of questionnaires were analysable. CRF prevalence was 43% (68 of 160). CRF associations included moderate/severe urinary symptoms, anxiety and medical co-morbidities; the strongest associations were depression [odds ratio (OR) 9.8, 95% confidence interval (CI) 4.3-22.8] and pain (OR 9.2, 95% CI 4.0-21.5). After controlling for other factors, the independent associations were depression (OR 4.7, 95% CI 1.6-14.0) and pain (OR 3.1, 95% CI 1.0-8.9). There was no association with age, disease burden or treatment duration.

Conclusions: Two-fifths of men with biochemically controlled prostate cancer on long-term ADT report CRF that interferes with function. Management aimed at improving CRF should address depression and pain.

Original languageEnglish
Pages (from-to)1542-+
Number of pages8
JournalAnnals of Oncology
Volume23
Issue number6
DOIs
Publication statusPublished - Jun 2012

Keywords / Materials (for Non-textual outputs)

  • RADIOTHERAPY
  • ASYMPTOMATIC MEN
  • MORBIDITY
  • QUALITY-OF-LIFE
  • DEPRESSION SCALE
  • fatigue
  • EORTC QLQ-C30
  • androgen deprivation
  • prostate
  • HOSPITAL ANXIETY
  • MORTALITY
  • POPULATION
  • cancer
  • hormone
  • RESISTANCE EXERCISE

Fingerprint

Dive into the research topics of 'Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy'. Together they form a unique fingerprint.

Cite this